Beth Staab, MD
Neurology · Bloomington, MNNPI 1295911238
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,150 of the $1,189 with a category attached, or 96.7%. AbbVie accounts for 96.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $750 and has fallen 97.3% since, to $20 in 2024.
Across 5 payments — averaging $237.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AVEO Pharmaceuticals, Inc.$20
- MDD US Operations, LLC$19
What the payments were for
- Speaking & faculty fees$1,15097%
- Food & beverage$202%
- Education$192%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $1,150 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| MDD US Operations, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$1,150
How this compares
$1,189 in reported general payments places this provider in the 70th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 13 | $92,622 |
| FycompaPerampanel | 21 | $23,609 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $19,480 |
| RytaryCarbidopa/Levodopa | 17 | $13,357 |
| Emgality PenGalcanezumab-Gnlm | 15 | $10,880 |
| Carbamazepine ErCarbamazepine | 34 | $6,503 |
| Levetiracetam | 175 | $6,075 |
| Lamotrigine ErLamotrigine | 13 | $5,924 |
| Memantine Hcl ErMemantine Hcl | 18 | $4,826 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 102 | $4,202 |
| Droxidopa | 11 | $3,989 |
| Lamotrigine | 95 | $3,870 |
| DilantinPhenytoin Sodium Extended | 19 | $3,440 |
| Oxcarbazepine | 32 | $3,013 |
| Gabapentin | 91 | $2,315 |
Paid to pharmacies, not to this prescriber.
Other neurology in Bloomington
- Eleanor OrehekBloomington$55K
- Jesse CorryBloomington$46K
- Jeffery AllenMinneapolis$1.1M
- Jonathan CalkwoodGolden Valley$493K
- Alejandro RabinsteinRochester$305K
- Patricia PenovichSaint Paul$304K
- Sean PittockRochester$231K
- Irfan AltafullahGolden Valley$203K
- Jessica StulcGolden Valley$199K
- Akram DastagirGolden Valley$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.